- Home
- SNTI vs CLGN Comparison
SNTI vs CLGN Comparison
Compare SNTI & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CLGN
- Stock Information
- Founded
- SNTI 2016
- CLGN 2004
- Country
- SNTI United States
- CLGN Israel
- Employees
- SNTI N/A
- CLGN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- SNTI Health Care
- CLGN Health Care
- Exchange
- SNTI Nasdaq
- CLGN Nasdaq
- Market Cap
- SNTI 39.6M
- CLGN 33.8M
- IPO Year
- SNTI N/A
- CLGN N/A
- Fundamental
- Price
- SNTI $1.37
- CLGN $2.62
- Analyst Decision
- SNTI Strong Buy
- CLGN Strong Buy
- Analyst Count
- SNTI 2
- CLGN 2
- Target Price
- SNTI $8.50
- CLGN $11.50
- AVG Volume (30 Days)
- SNTI 120.0K
- CLGN 25.4K
- Earning Date
- SNTI 11-13-2025
- CLGN 08-20-2025
- Dividend Yield
- SNTI N/A
- CLGN N/A
- EPS Growth
- SNTI N/A
- CLGN N/A
- EPS
- SNTI N/A
- CLGN N/A
- Revenue
- SNTI N/A
- CLGN $2,402,000.00
- Revenue This Year
- SNTI N/A
- CLGN $1,617.28
- Revenue Next Year
- SNTI $150.00
- CLGN $83.54
- P/E Ratio
- SNTI N/A
- CLGN N/A
- Revenue Growth
- SNTI N/A
- CLGN 248.62
- 52 Week Low
- SNTI $1.26
- CLGN $1.31
- 52 Week High
- SNTI $16.94
- CLGN $5.00
- Technical
- Relative Strength Index (RSI)
- SNTI 37.01
- CLGN 51.52
- Support Level
- SNTI $1.33
- CLGN $2.38
- Resistance Level
- SNTI $1.39
- CLGN $2.76
- Average True Range (ATR)
- SNTI 0.08
- CLGN 0.17
- MACD
- SNTI 0.01
- CLGN -0.03
- Stochastic Oscillator
- SNTI 31.43
- CLGN 48.78
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.